THYROID CANCER DIAGNOSTICS
Disclosed herein, in certain instances, are methods for the diagnosis, prognosis and determination of cancer progression of a cancer in a subject. Further disclosed herein, in certain instances, are methods for determining the treatment modality of a cancer in a subject. The methods comprise expression-based analysis of targets. Further disclosed herein, in certain instances, are probe sets for use in assessing a cancer status in a subject.
1 .- 50 . (canceled)
51 . A method comprising:
(a) obtaining a sample of a subject, wherein said subject has or is suspected of having a cancer;
(b) assaying an expression level in said sample for a plurality of targets, wherein: (i) the plurality of targets comprises one or more targets selected from a target listed in Table 6; (ii) the plurality of targets comprises one or more targets comprising a sequence selected from SEQ ID NOs: 1-153; (iii) the plurality of targets comprises one or more targets comprises a sequence that is a complement of a sequence selected from SEQ ID NOs: 1-153; (iv) the plurality of targets comprises one or more targets comprises a sequence that is a reverse complement of a sequence selected from SEQ ID NOs: 1-153; or a combination of (i-iv); and
(c) outputting a report, wherein said report comprises a representation of said expression levels measured in (b).
52 . The method of claim 51 , wherein said cancer is a thyroid cancer.
53 . The method of claim 51 , wherein said cancer is a lung cancer.
54 . The method of claim 51 , wherein said cancer is a prostate cancer.
55 . The method of claim 51 , wherein said cancer is a pancreatic cancer.
56 . The method of claim 51 , wherein said cancer comprises a carcinoma, a sarcoma, a leukemia, a lymphoma, a myeloma, or a tumor.
57 . The method of claim 51 , wherein said cancer is a skin cancer, a lung cancer, a colon cancer, a pancreatic cancer, a prostate cancer, a liver cancer, a thyroid cancer, an ovarian cancer, an uterine cancer, a breast cancer, a cervical cancer, a kidney cancer, an epithelial carcinoma, a squamous carcinoma, a basal cell carcinoma, a melanoma, a papilloma, or an adenoma.
58 . The method of claim 51 , wherein said plurality of targets comprises a nucleic acid sequence.
59 . The method of claim 57 , wherein said nucleic acid sequence is a DNA sequence.
60 . The method of claim 57 , wherein said nucleic acid sequence is an RNA sequence.
61 . The method of claim 51 , further comprising assaying an expression level of a miRNA.
62 . The method of claim 51 , further comprising assaying an expression level of a siRNA.
63 . The method of claim 51 , further comprising assaying an expression level of a snoRNA.
64 . The method of claim 51 , further comprising assaying an expression level of a lincRNA.
65 . The method of claim 51 , wherein said assaying comprises nucleic acid hybridization or nucleic acid amplification.
66 . The method of claim 51 , further comprising administering a chemotherapeutic agent or radiation treatment to said subject.
67 . The method of claim 51 , wherein said report comprises a recommendation of a treatment for said subject.